

Yong Song

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1064716/publications.pdf>

Version: 2024-02-01

212
papers

7,542
citations

66250

44
h-index

84171

75
g-index

216
all docs

216
docs citations

216
times ranked

12574
citing authors

#	ARTICLE	IF	CITATIONS
1	Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. <i>Lancet Oncology</i> , The, 2013, 14, 953-961.	5.1	389
2	Encephalitis as a clinical manifestation of COVID-19. <i>Brain, Behavior, and Immunity</i> , 2020, 88, 945-946.	2.0	345
3	Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. <i>Journal of Medical Virology</i> , 2020, 92, 1890-1901.	2.5	334
4	A critical role for the long non-coding RNA GAS5 in proliferation and apoptosis in non-small cell lung cancer. <i>Molecular Carcinogenesis</i> , 2015, 54, E1-E12.	1.3	261
5	Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology) Tj ETQq1 1 0.784314288 / Over	0.784314288	142
6	Prolonged SARS-CoV-2 RNA shedding: Not a rare phenomenon. <i>Journal of Medical Virology</i> , 2020, 92, 2286-2287.	2.5	177
7	Downregulation of GSDMD attenuates tumor proliferation via the intrinsic mitochondrial apoptotic pathway and inhibition of EGFR/Akt signaling and predicts a good prognosis in non-small cell lung cancer. <i>Oncology Reports</i> , 2018, 40, 1971-1984.	1.2	169
8	Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial. <i>Lancet Respiratory Medicine</i> , the, 2018, 6, 681-690.	5.2	166
9	The growth arrest-specific transcript 5 (GAS5): a pivotal tumor suppressor long noncoding RNA in human cancers. <i>Tumor Biology</i> , 2016, 37, 1437-1444.	0.8	159
10	Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients. <i>Journal of Translational Medicine</i> , 2019, 17, 355.	1.8	150
11	The long non-coding RNA HNF1A-AS1 regulates proliferation and metastasis in lung adenocarcinoma. <i>Oncotarget</i> , 2015, 6, 9160-9172.	0.8	141
12	The role of TWIST1 in epithelial-mesenchymal transition and cancers. <i>Tumor Biology</i> , 2016, 37, 185-197.	0.8	133
13	Tumor-derived exosomal lncRNA GAS5 as a biomarker for early-stage non-small cell lung cancer diagnosis. <i>Journal of Cellular Physiology</i> , 2019, 234, 20721-20727.	2.0	118
14	GSDMD is required for effector CD8+ T cell responses to lung cancer cells. <i>International Immunopharmacology</i> , 2019, 74, 105713.	1.7	114
15	Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial. <i>Lancet Respiratory Medicine</i> , the, 2020, 8, 45-53.	5.2	105
16	Downregulation of the long noncoding RNA GAS5-AS1 contributes to tumor metastasis in non-small cell lung cancer. <i>Scientific Reports</i> , 2016, 6, 31093.	1.6	102
17	Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study. <i>Cancer Cell</i> , 2021, 39, 1279-1291.e3.	7.7	99
18	Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis. <i>Translational Lung Cancer Research</i> , 2017, 6, S8-S20.	1.3	97

#	ARTICLE	IF	CITATIONS
19	The association of PD-L1 expression with the efficacy of anti-PD-1/PD-L1 immunotherapy and survival of non-small cell lung cancer patients: a meta-analysis of randomized controlled trials. <i>Translational Lung Cancer Research</i> , 2019, 8, 413-428.	1.3	95
20	Concomitant neurological symptoms observed in a patient diagnosed with coronavirus disease 2019. <i>Journal of Medical Virology</i> , 2020, 92, 1782-1784.	2.5	93
21	Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment. <i>Translational Lung Cancer Research</i> , 2019, 8, 302-316.	1.3	91
22	Combination of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio is a useful prognostic factor in advanced non-small cell lung cancer patients. <i>Thoracic Cancer</i> , 2015, 6, 275-287.	0.8	88
23	PRC1 contributes to tumorigenesis of lung adenocarcinoma in association with the Wnt/ β -catenin signaling pathway. <i>Molecular Cancer</i> , 2017, 16, 108.	7.9	81
24	Expression profiles and clinical value of plasma exosomal Tim-3 and Galectin-9 in non-small cell lung cancer. <i>Biochemical and Biophysical Research Communications</i> , 2018, 498, 409-415.	1.0	81
25	The biology, function and clinical implications of exosomes in lung cancer. <i>Cancer Letters</i> , 2017, 407, 84-92.	3.2	78
26	Diagnostic Accuracy of CT-Guided Transthoracic Needle Biopsy for Solitary Pulmonary Nodules. <i>PLoS ONE</i> , 2015, 10, e0131373.	1.1	76
27	Intratracheal administration of mitochondrial DNA directly provokes lung inflammation through the TLR9-p38 MAPK pathway. <i>Free Radical Biology and Medicine</i> , 2015, 83, 149-158.	1.3	76
28	Two plasma microRNA panels for diagnosis and subtype discrimination of lung cancer. <i>Lung Cancer</i> , 2018, 123, 44-51.	0.9	75
29	Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study. <i>Journal of Thoracic Oncology</i> , 2021, 16, 2109-2120.	0.5	75
30	PTP1B promotes cell proliferation and metastasis through activating src and ERK1/2 in non-small cell lung cancer. <i>Cancer Letters</i> , 2015, 359, 218-225.	3.2	73
31	Pretreatment platelet-to-lymphocyte ratio (PLR) as a predictor of response to first-line platinum-based chemotherapy and prognosis for patients with non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2013, 5, 783-9.	0.6	73
32	NatD promotes lung cancer progression by preventing histone H4 serine phosphorylation to activate Slug expression. <i>Nature Communications</i> , 2017, 8, 928.	5.8	69
33	Extracellular mitochondrial DNA promote NLRP3 inflammasome activation and induce acute lung injury through TLR9 and NF- κ B. <i>Journal of Thoracic Disease</i> , 2019, 11, 4816-4828.	0.6	67
34	Upregulation of long intergenic noncoding RNA 00673 promotes tumor proliferation via LSD1 interaction and repression of NCALD in non-small-cell lung cancer. <i>Oncotarget</i> , 2016, 7, 25558-25575.	0.8	66
35	Prognostic role of pretreatment neutrophil-to-lymphocyte ratio in non-small cell lung cancer patients treated with systemic therapy: a meta-analysis. <i>Translational Lung Cancer Research</i> , 2019, 8, 214-226.	1.3	66
36	Pulmonary ground-glass opacity: computed tomography features, histopathology and molecular pathology. <i>Translational Lung Cancer Research</i> , 2017, 6, 68-75.	1.3	64

#	ARTICLE	IF	CITATIONS
37	Circulating tumor DNA clearance predicts prognosis across treatment regimen in a large real-world longitudinally monitored advanced non-small cell lung cancer cohort. <i>Translational Lung Cancer Research</i> , 2020, 9, 269-279.	1.3	64
38	A Serum Vitamin D Level $\leq 25\text{nmol/L}$ Pose High Tuberculosis Risk: A Meta-Analysis. <i>PLoS ONE</i> , 2015, 10, e0126014.	1.1	61
39	Long non-coding RNA 00312 regulated by HOXA5 inhibits tumour proliferation and promotes apoptosis in Non-small cell lung cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2017, 21, 2184-2198.	1.6	59
40	Low-dose carboplatin reprograms tumor immune microenvironment through STING signaling pathway and synergizes with PD-1 inhibitors in lung cancer. <i>Cancer Letters</i> , 2021, 500, 163-171.	3.2	55
41	The clinicopathological and prognostic significance of PD-L1 expression assessed by immunohistochemistry in lung cancer: a meta-analysis of 50 studies with 11,383 patients. <i>Translational Lung Cancer Research</i> , 2019, 8, 429-449.	1.3	54
42	Long intergenic noncoding RNA 00673 promotes non-small-cell lung cancer metastasis by binding with EZH2 and causing epigenetic silencing of HOXA5. <i>Oncotarget</i> , 2017, 8, 32696-32705.	0.8	51
43	Comparison between endobronchial ultrasound-guided transbronchial biopsy and CT-guided transthoracic lung biopsy for the diagnosis of peripheral lung cancer: a systematic review and meta-analysis. <i>Translational Lung Cancer Research</i> , 2017, 6, 23-34.	1.3	50
44	TLR4 mediates LPS-induced HO-1 expression in mouse liver: Role of TNF- α and IL-1 β . <i>World Journal of Gastroenterology</i> , 2003, 9, 1799.	1.4	48
45	Crocin inhibits cell proliferation and enhances cisplatin and pemetrexed chemosensitivity in lung cancer cells. <i>Translational Lung Cancer Research</i> , 2015, 4, 775-83.	1.3	48
46	sRAGE alleviates neutrophilic asthma by blocking HMGB1/RAGE signalling in airway dendritic cells. <i>Scientific Reports</i> , 2017, 7, 14268.	1.6	45
47	LncRNA GMDSAS1 inhibits lung adenocarcinoma development by regulating miR-96/CYLD signaling. <i>Cancer Medicine</i> , 2020, 9, 1196-1208.	1.3	45
48	PD-L1 over-expression and survival in patients with non-small cell lung cancer: a meta-analysis. <i>Translational Lung Cancer Research</i> , 2015, 4, 203-8.	1.3	43
49	NCAPG2 promotes tumour proliferation by regulating G2/M phase and associates with poor prognosis in lung adenocarcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2017, 21, 665-676.	1.6	41
50	Anti-HMGB1 Neutralizing Antibody Ameliorates Neutrophilic Airway Inflammation by Suppressing Dendritic Cell-Mediated Th17 Polarization. <i>Mediators of Inflammation</i> , 2014, 2014, 1-11.	1.4	39
51	Detection of EML4-ALK in Lung Adenocarcinoma Using Pleural Effusion with FISH, IHC, and RT-PCR Methods. <i>PLoS ONE</i> , 2015, 10, e0117032.	1.1	39
52	Elevated pretreatment serum globulin albumin ratio predicts poor prognosis for advanced non-small cell lung cancer patients. <i>Journal of Thoracic Disease</i> , 2014, 6, 1261-70.	0.6	39
53	The overexpression of KIFC1 was associated with the proliferation and prognosis of non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2016, 8, 2911-2923.	0.6	37
54	PiggyBac transposon vectors: the tools of the human gene encoding. <i>Translational Lung Cancer Research</i> , 2016, 5, 120-5.	1.3	36

#	ARTICLE	IF	CITATIONS
55	PaO ₂ /FiO ₂ and IL-6 are risk factors of mortality for intensive care COVID-19 patients. <i>Scientific Reports</i> , 2021, 11, 7334.	1.6	35
56	Identification of novel driver mutations of the discoidin domain receptor 2 (DDR2) gene in squamous cell lung cancer of Chinese patients. <i>BMC Cancer</i> , 2014, 14, 369.	1.1	33
57	Effectiveness and safety of PD-1/PD-L1 or CTLA4 inhibitors combined with chemotherapy as a first-line treatment for lung cancer: A meta-analysis. <i>Journal of Thoracic Disease</i> , 2018, 10, 6636-6652.	0.6	33
58	TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib. <i>Journal of Thoracic Disease</i> , 2018, 10, 2991-2998.	0.6	31
59	The effect of P2X7 receptor 1513 polymorphism on susceptibility to tuberculosis: A meta-analysis. <i>Infection, Genetics and Evolution</i> , 2014, 24, 82-91.	1.0	30
60	Recombinant HMGB1 A box protein inhibits Th17 responses in mice with neutrophilic asthma by suppressing dendritic cell-mediated Th17 polarization. <i>International Immunopharmacology</i> , 2015, 24, 110-118.	1.7	30
61	<scp>TEAD</scp>4 exerts pro-metastatic effects and is negatively regulated by miR6839 in lung adenocarcinoma progression. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 3560-3571.	1.6	30
62	Clinical characteristics, laboratory abnormalities and CT findings of COVID-19 patients and risk factors of severe disease: a systematic review and meta-analysis. <i>Annals of Palliative Medicine</i> , 2021, 10, 1928-1949.	0.5	30
63	Patterns and functional implications of platelets upon tumor "education". <i>International Journal of Biochemistry and Cell Biology</i> , 2017, 90, 68-80.	1.2	28
64	A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506). <i>BMC Cancer</i> , 2017, 17, 462.	1.1	28
65	Inhibition of GGPPS1 attenuated LPS-induced acute lung injury and was associated with NLRP3 inflammasome suppression. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2019, 316, L567-L577.	1.3	28
66	Elevated exosome-derived miRNAs predict osimertinib resistance in non-small cell lung cancer. <i>Cancer Cell International</i> , 2021, 21, 428.	1.8	28
67	Targeting the ubiquitination/deubiquitination process to regulate immune checkpoint pathways. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 28.	7.1	28
68	Combination of computed tomography imaging-based radiomics and clinicopathological characteristics for predicting the clinical benefits of immune checkpoint inhibitors in lung cancer. <i>Respiratory Research</i> , 2021, 22, 189.	1.4	27
69	Peripheral Blood Biomarkers for Early Diagnosis, Severity, and Prognosis of Checkpoint Inhibitor-Related Pneumonitis in Patients With Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 698832.	1.3	27
70	MET-UBE2H Fusion as a Novel Mechanism of Acquired EGFR Resistance in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2018, 13, e202-e204.	0.5	26
71	Immune-Related Adverse Events Predict the Efficacy of Immune Checkpoint Inhibitors in Lung Cancer Patients: A Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 631949.	1.3	26
72	Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1403-1414.	0.5	26

#	ARTICLE	IF	CITATIONS
73	Efficacy and safety of Abraxane in treatment of progressive and recurrent non-small cell lung cancer patients: A retrospective clinical study. <i>Thoracic Cancer</i> , 2012, 3, 341-347.	0.8	25
74	Computed tomography and clinical features associated with epidermal growth factor receptor mutation status in stage I/II lung adenocarcinoma. <i>Thoracic Cancer</i> , 2017, 8, 260-270.	0.8	25
75	Management strategy of solitary pulmonary nodules. <i>Journal of Thoracic Disease</i> , 2013, 5, 824-9.	0.6	25
76	Can EGFR mutations in plasma or serum be predictive markers of non-small-cell lung cancer? A meta-analysis. <i>Lung Cancer</i> , 2015, 88, 246-253.	0.9	24
77	Biomarkers for patients with trauma associated acute respiratory distress syndrome. <i>Military Medical Research</i> , 2017, 4, 25.	1.9	24
78	ALK and ROS1 rearrangements, coexistence and treatment in epidermal growth factor receptor-wild type lung adenocarcinoma: a multicenter study of 732 cases. <i>Journal of Thoracic Disease</i> , 2017, 9, 3919-3926.	0.6	24
79	WNT5B exerts oncogenic effects and is negatively regulated by miR-5587-3p in lung adenocarcinoma progression. <i>Oncogene</i> , 2020, 39, 1484-1497.	2.6	24
80	Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA Sequencing. <i>Journal of Thoracic Oncology</i> , 2021, 16, 827-839.	0.5	24
81	Metastasis-associated fibroblasts: an emerging target for metastatic cancer. <i>Biomarker Research</i> , 2021, 9, 47.	2.8	24
82	CDCA7 promotes lung adenocarcinoma proliferation via regulating the cell cycle. <i>Pathology Research and Practice</i> , 2019, 215, 152559.	1.0	23
83	Prognostic value of FGFR1 gene copy number in patients with non-small cell lung cancer: a meta-analysis. <i>Journal of Thoracic Disease</i> , 2014, 6, 803-9.	0.6	23
84	Prognostic significance of β -catenin expression in patients with non-small cell lung cancer: a meta-analysis. <i>Translational Lung Cancer Research</i> , 2017, 6, 97-108.	1.3	22
85	Overexpression of geranylgeranyl diphosphate synthase contributes to tumour metastasis and correlates with poor prognosis of lung adenocarcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 2177-2189.	1.6	22
86	EGFR-RAD51 fusion variant in lung adenocarcinoma and response to erlotinib: A case report. <i>Lung Cancer</i> , 2018, 115, 131-134.	0.9	22
87	Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line Chemotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 432-439.	0.6	21
88	Chinese Expert Recommendation for Diagnosis and Treatment of Massive Hemoptysis. <i>Respiration</i> , 2020, 99, 83-92.	1.2	21
89	Something in need is something indeed. <i>Translational Lung Cancer Research</i> , 2012, 1, 1-2.	1.3	21
90	Prognostic value of the expression of estrogen receptor β in patients with non-small cell lung cancer: a meta-analysis. <i>Translational Lung Cancer Research</i> , 2016, 5, 202-207.	1.3	20

#	ARTICLE	IF	CITATIONS
91	Anti-angiogenic efficacy of 5â€²-triphosphate siRNA combining VEGF silencing and RIG-I activation in NSCLCs. <i>Oncotarget</i> , 2015, 6, 29664-29674.	0.8	20
92	Clinical outcomes of cyberknife stereotactic radiosurgery for lung metastases. <i>Journal of Thoracic Disease</i> , 2015, 7, 407-12.	0.6	20
93	Correlation in histological subtypes with high resolution computed tomography signatures of early stage lung adenocarcinoma. <i>Translational Lung Cancer Research</i> , 2017, 6, 14-22.	1.3	19
94	Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal Circulating Tumor DNA Monitoring in Advanced EGFR-Mutant Lung Adenocarcinoma Under Gefitinib Treatment. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1857-1870.	0.5	19
95	Biomarkers of Osimertinib Response in Patients with Refractory, EGFR-T790Mâ€“positive Nonâ€“Small Cell Lung Cancer and Central Nervous System Metastases: The APOLLO Study. <i>Clinical Cancer Research</i> , 2020, 26, 6168-6175.	3.2	19
96	Blocking SphK1/S1P/S1PR1 Signaling Pathway Alleviates Lung Injury Caused by Sepsis in Acute Ethanol Intoxication Mice. <i>Inflammation</i> , 2021, 44, 2170-2179.	1.7	19
97	Diagnostic and therapeutic value of progastrinâ€“releasing peptide on smallâ€“cell lung cancer: A Singleâ€“Center Experience in China. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 4328-4334.	1.6	18
98	Topotecan Alleviates Lipopolysaccharide-Mediated Acute Lung Injury Via the NF-â€šB Signaling Pathway. <i>Journal of Surgical Research</i> , 2019, 235, 83-92.	0.8	18
99	Pemetrexed-based chemotherapy for non-small-cell lung cancer patients with EGFR exon 20 insertion mutation: a multicenter study. <i>Translational Lung Cancer Research</i> , 2020, 9, 1853-1861.	1.3	18
100	RNA sequencing enables systematic identification of platelet transcriptomic alterations in NSCLC patients. <i>Biomedicine and Pharmacotherapy</i> , 2018, 105, 204-214.	2.5	17
101	Molecular Characteristics and Clinical Outcomes of EGFR Exon 19 C-Helix Deletion in Nonâ€“Small Cell Lung Cancer and Response to EGFR TKIs. <i>Translational Oncology</i> , 2020, 13, 100791.	1.7	17
102	Immune checkpoint inhibitors alone vs immune checkpoint inhibitorsâ€“combined chemotherapy for NSCLC patients with high PD-L1 expression: a network meta-analysis. <i>British Journal of Cancer</i> , 2022, 127, 948-956.	2.9	17
103	Conventional Hypoglycaemic Agents and the Risk of Lung Cancer in Patients with Diabetes: A Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e99577.	1.1	16
104	Video-assisted thoracoscopic surgery and thoracotomy during lobectomy for clinical stage I non-small-cell lung cancer have equivalent oncological outcomes: A single-center experience of 212 consecutive resections. <i>Oncology Letters</i> , 2015, 9, 1364-1372.	0.8	16
105	Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology. <i>Cancer Biology and Medicine</i> , 2019, 16, 189.	1.4	16
106	The KIF5B-RET Fusion Gene Mutation as a Novel Mechanism of Acquired EGFR Tyrosine Kinase Inhibitor Resistance in Lung Adenocarcinoma. <i>Clinical Lung Cancer</i> , 2019, 20, e73-e76.	1.1	16
107	Geranylgeranyl diphosphate synthase 1 knockout ameliorates ventilator-induced lung injury via regulation of TLR2/4-AP-1 signaling. <i>Free Radical Biology and Medicine</i> , 2020, 147, 159-166.	1.3	16
108	Twist1-mediated 4E-BP1 regulation through mTOR in non-small cell lung cancer. <i>Oncotarget</i> , 2015, 6, 33006-33018.	0.8	16

#	ARTICLE	IF	CITATIONS
109	Circulating soluble intercellular adhesion molecule-1 in lung cancer: a systematic review. <i>Translational Lung Cancer Research</i> , 2012, 1, 36-44.	1.3	16
110	Potential mechanism of primary resistance to icotinib in patients with advanced non-small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: A multicenter study. <i>Cancer Science</i> , 2020, 111, 679-686.	1.7	15
111	A large real-world cohort study of examined lymph node standards for adequate nodal staging in early non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 815-825.	1.3	15
112	Prognostic value of wingless-type proteins in non-small cell lung cancer patients: a meta-analysis. <i>Translational Lung Cancer Research</i> , 2016, 5, 436-442.	1.3	15
113	Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety From a Phase 2 Study in People's Republic of China. <i>Journal of Thoracic Oncology</i> , 2022, 17, 816-826.	0.5	15
114	Combining stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 4368-4379.	1.3	15
115	Biodegradable Porous Polymeric Drug with pH-Stimuli-Responsive Delivery Capacity for Combined Cancer Therapy. <i>ACS Applied Polymer Materials</i> , 2022, 4, 714-724.	2.0	15
116	The role of serum carcinoembryonic antigen in predicting responses to chemotherapy and survival in patients with non-small cell lung cancer. <i>Journal of Cancer Research and Therapeutics</i> , 2014, 10, 239.	0.3	14
117	Lung adenocarcinoma patient with an EGFR kinase domain duplication (KDD) and the response to icotinib. <i>Journal of Thoracic Disease</i> , 2018, 10, E359-E363.	0.6	14
118	Plasma mtDNA Analysis Aids in Predicting Pancreatic Necrosis in Acute Pancreatitis Patients: A Pilot Study. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2975-2982.	1.1	14
119	Zebrafish Xenograft Model of Human Lung Cancer for Evaluating Osimertinib Resistance. <i>BioMed Research International</i> , 2019, 2019, 1-10.	0.9	14
120	Comparison between closed pleural biopsy and medical thoracoscopy for the diagnosis of undiagnosed exudative pleural effusions: a systematic review and meta-analysis. <i>Translational Lung Cancer Research</i> , 2020, 9, 446-458.	1.3	14
121	The diagnostic yield of closed needle pleural biopsy in exudative pleural effusion: a retrospective 10-year study. <i>Annals of Translational Medicine</i> , 2020, 8, 491-491.	0.7	14
122	Early diagnosis of solitary pulmonary nodules. <i>Journal of Thoracic Disease</i> , 2013, 5, 830-40.	0.6	14
123	Effect of Adjuvant Chemotherapy on Survival of Patients With 8th Edition Stage IB Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 784289.	1.3	14
124	Lipid Metabolism: Immune Regulation and Therapeutic Prospectives in Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2022, 13, 860586.	2.2	14
125	Predictive and prognostic significance of circulating endothelial cells in advanced non-small cell lung cancer patients. <i>Tumor Biology</i> , 2015, 36, 9031-9037.	0.8	13
126	Adenosine Triphosphate Promotes Allergen-Induced Airway Inflammation and Th17 Cell Polarization in Neutrophilic Asthma. <i>Journal of Immunology Research</i> , 2017, 2017, 1-10.	0.9	13

#	ARTICLE	IF	CITATIONS
127	Protein regulator of cytokinesis-1 expression: prognostic value in lung squamous cell carcinoma patients. <i>Journal of Thoracic Disease</i> , 2017, 9, 2054-2060.	0.6	13
128	Plasma long noncoding RNA IL-7R as a prognostic biomarker for clinical outcomes in patients with acute respiratory distress syndrome. <i>Clinical Respiratory Journal</i> , 2018, 12, 1607-1614.	0.6	13
129	Irinotecan, topotecan, paclitaxel or docetaxel for second-line treatment of small cell lung cancer: a single-center retrospective study of efficiency comparison and prognosis analysis. <i>Translational Lung Cancer Research</i> , 2019, 8, 829-837.	1.3	13
130	Diagnostic Value of Mutation-Specific Antibodies for Immunohistochemical Detection of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e105940.	1.1	12
131	Prognostic value of secreted phosphoprotein-1 in pleural effusion associated with non-small cell lung cancer. <i>BMC Cancer</i> , 2014, 14, 280.	1.1	12
132	Topotecan alleviates ventilator-induced lung injury via NF- κ B pathway inhibition. <i>Cytokine</i> , 2018, 110, 381-388.	1.4	12
133	Identification of a Novel Icotinib-Sensitive EGFR-SEPTIN14 Fusion Variant in Lung Adenocarcinoma by Next-Generation Sequencing. <i>Journal of Thoracic Oncology</i> , 2019, 14, e181-e183.	0.5	12
134	A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer – The FALUCA study. <i>Lung Cancer</i> , 2020, 146, 252-262.	0.9	12
135	Pseudogene KRT17P3 drives cisplatin resistance of human NSCLC cells by modulating miR-497a-5p/mTOR. <i>Cancer Science</i> , 2021, 112, 275-286.	1.7	12
136	Prognostic value of lymph node ratio in patients with pathological N1 non-small cell lung cancer: a systematic review with meta-analysis. <i>Translational Lung Cancer Research</i> , 2016, 5, 258-264.	1.3	11
137	Comparison of clinical and radiological characteristics between anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation in treatment naïve advanced lung adenocarcinoma. <i>Journal of Thoracic Disease</i> , 2017, 9, 3927-3937.	0.6	11
138	A Patient With Lung Adenocarcinoma With BRAF Gene Fusion and Response to Vemurafenib. <i>Clinical Lung Cancer</i> , 2019, 20, e224-e228.	1.1	11
139	The Predictive Value of Clinical and Molecular Characteristics or Immunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Oncology</i> , 2021, 11, 732214.	1.3	11
140	The imaging of small pulmonary nodules. <i>Translational Lung Cancer Research</i> , 2017, 6, 62-67.	1.3	10
141	Simultaneous VENTANA IHC and RT-PCR testing of ALK status in Chinese non-small cell lung cancer patients and response to crizotinib. <i>Journal of Translational Medicine</i> , 2018, 16, 93.	1.8	10
142	Real-world efficacy and potential mechanism of resistance of icotinib in Asian advanced non-small cell lung cancer with EGFR uncommon mutations: A multicenter study. <i>Cancer Medicine</i> , 2020, 9, 12-18.	1.3	10
143	CD39+ Regulatory T Cells Attenuate Lipopolysaccharide-Induced Acute Lung Injury via Autophagy and the ERK/FOS Pathway. <i>Frontiers in Immunology</i> , 2020, 11, 602605.	2.2	10
144	Serum Exosomal miRNA Might Be a Novel Liquid Biopsy to Identify Leptomeningeal Metastasis in Non-Small Cell Lung Cancer. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 2327-2335.	1.0	10

#	ARTICLE	IF	CITATIONS
145	Lesion with morphologic feature of organizing pneumonia (OP) in CT-guided lung biopsy samples for diagnosis of bronchiolitis obliterans organizing pneumonia (BOOP): a retrospective study of 134 cases in a single center. <i>Journal of Thoracic Disease</i> , 2014, 6, 1251-60.	0.6	10
146	Transthoracic needle aspiration in solitary pulmonary nodule. <i>Translational Lung Cancer Research</i> , 2017, 6, 76-85.	1.3	9
147	Evaluation of the Lung Immune Prognostic Index in Non-Small Cell Lung Cancer Patients Treated With Systemic Therapy: A Retrospective Study and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 670230.	1.3	9
148	A Novel Third-generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-mutant Non-Small Cell Lung Cancer: a Multicenter Phase I/II Study. <i>Clinical Cancer Research</i> , 2022, 28, 1127-1135.	3.2	9
149	AS-tDR-007872: A Novel tRNA-Derived Small RNA Acts an Important Role in Non-Small-Cell Lung Cancer. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-11.	0.7	9
150	Clinical outcomes of CyberKnife stereotactic radiosurgery for elderly patients with presumed primary stage I lung cancer. <i>Translational Lung Cancer Research</i> , 2017, 6, 6-13.	1.3	8
151	Eosinophil peroxidase over-expression predicts the clinical outcome of patients with primary lung adenocarcinoma. <i>Journal of Cancer</i> , 2019, 10, 1032-1038.	1.2	8
152	Efficacy of rapid on-site evaluation for diagnosing pulmonary lesions and mediastinal lymph nodes: a systematic review and meta-analysis. <i>Translational Lung Cancer Research</i> , 2019, 8, 1029-1044.	1.3	8
153	Association of the metformin with the risk of lung cancer: a meta-analysis. <i>Translational Lung Cancer Research</i> , 2013, 2, 259-63.	1.3	8
154	A Multicenter Retrospective Study on the Prognosis of Stage III Unresectable Mutant Non-Small Cell Lung Cancer With Tyrosine Kinase Inhibitors Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 692703.	1.3	7
155	A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel. <i>Translational Lung Cancer Research</i> , 2018, 7, 428-436.	1.3	7
156	Diagnostic and prognostic significance of lysophosphatidic acid in malignant pleural effusions. <i>Journal of Thoracic Disease</i> , 2014, 6, 483-90.	0.6	7
157	Response to first-line chemotherapy of docetaxel combined with platinum predicting the prognosis and subsequent treatment of patients with non-small cell lung cancer. <i>Thoracic Cancer</i> , 2014, 5, 337-342.	0.8	6
158	Chloroquine inhibits tumor growth and angiogenesis in malignant pleural effusion. <i>Tumor Biology</i> , 2016, 37, 16249-16258.	0.8	6
159	Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status. <i>Scientific Reports</i> , 2017, 7, 8483.	1.6	6
160	Rhubarb vs. glycerin enema for treatment of critically ill patients with intra-abdominal hypertension. <i>Experimental and Therapeutic Medicine</i> , 2017, 14, 855-861.	0.8	6
161	A novel co-existing <i>ZCCHC8-ROS1</i> and de-novo <i>MET</i> amplification dual driver in advanced lung adenocarcinoma with a good response to crizotinib. <i>Cancer Biology and Therapy</i> , 2018, 19, 1097-1101.	1.5	6
162	Combination of apatinib and docetaxel in treating advanced non-squamous non-small cell lung cancer patients with wild-type EGFR: a multi-center, phase II trial. <i>Journal of Thoracic Disease</i> , 2020, 12, 2450-2458.	0.6	6

#	ARTICLE	IF	CITATIONS
163	Novel risk scoring system for immune checkpoint inhibitors treatment in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 776-789.	1.3	6
164	Antibiotic exposure windows and the efficacy of immune checkpoint blockers in patients with cancer: a meta-analysis. <i>Annals of Palliative Medicine</i> , 2021, 10, 2709-2722.	0.5	6
165	Association of MUC19 Mutation With Clinical Benefits of Anti-PD-1 Inhibitors in Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 596542.	1.3	6
166	International consensus on severe lung cancer—the first edition. <i>Translational Lung Cancer Research</i> , 2021, 10, 2633-2666.	1.3	6
167	Serum neurofilament light chain or glial fibrillary acidic protein in the diagnosis and prognosis of brain metastases. <i>Journal of Neurology</i> , 2022, 269, 815-823.	1.8	6
168	A narrative review of progress in diagnosis and treatment of small cell lung cancer patients with hyponatremia. <i>Translational Lung Cancer Research</i> , 2020, 9, 2469-2478.	1.3	6
169	F-circEA1 regulates cell proliferation and apoptosis through ALK downstream signaling pathway in non-small cell lung cancer. <i>Human Cell</i> , 2022, 35, 260-270.	1.2	6
170	Pollutional haze as a potential cause of lung cancer. <i>Journal of Thoracic Disease</i> , 2015, 7, E412-7.	0.6	6
171	MDT is still important in the treatment of early stage lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S3984-S3985.	0.6	5
172	The prognostic value of longitudinal circulating tumor DNA profiling during osimertinib treatment. <i>Translational Lung Cancer Research</i> , 2021, 10, 326-339.	1.3	5
173	Geranylgeranyl diphosphate synthase deficiency hyperactivates macrophages and aggravates lipopolysaccharide-induced acute lung injury. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2021, 320, L1011-L1024.	1.3	5
174	A narrative review of advances in treatment and survival prognosis of HER2-positive malignant lung cancers. <i>Journal of Thoracic Disease</i> , 2021, 13, 3708-3720.	0.6	5
175	Neoadjuvant Programmed Cell Death Protein 1 Blockade Combined With Stereotactic Body Radiation Therapy for Stage III(N2) Non-Small Cell Lung Cancer: A Case Series. <i>Frontiers in Oncology</i> , 2022, 12, 779251.	1.3	5
176	A standard for hilar and intrapulmonary lymph node dissection and pathological examination in early non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 4587-4599.	1.3	5
177	Recurrent "pneumonia" in left lower lobe lasting for 8 years: a case report. <i>Translational Lung Cancer Research</i> , 2016, 5, 356-362.	1.3	4
178	Three new disease-progression modes in NSCLC patients after EGFR-TKI treatment by next-generation sequencing analysis. <i>Lung Cancer</i> , 2018, 125, 43-50.	0.9	4
179	¹⁸ F-fluorodeoxyglucose positron emission tomography/computed tomography in the diagnosis of benign pulmonary lesions in sarcoidosis. <i>Translational Lung Cancer Research</i> , 2019, 8, 208-213.	1.3	4
180	Geranylgeranyl diphosphate synthase deficiency aggravates lung fibrosis in mice by modulating TGF- β 1/BMP-4 signaling. <i>Biological Chemistry</i> , 2019, 400, 1617-1627.	1.2	4

#	ARTICLE	IF	CITATIONS
181	Neutrophil-derived long noncoding RNA IL-7R predicts development of multiple organ dysfunction syndrome in patients with trauma. <i>European Journal of Trauma and Emergency Surgery</i> , 2020, , 1.	0.8	4
182	Contrast-enhanced computed tomography prior to percutaneous transthoracic needle biopsy reduces the incidence of hemorrhage. <i>Annals of Translational Medicine</i> , 2021, 9, 288-288.	0.7	4
183	Predictive and prognostic values of circulating tumor DNA (ctDNA) clearance in osimertinib treated advanced non-small cell lung cancer cohort.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3036-3036.	0.8	4
184	Detection of oncogenic mutations in resected bronchial margins by next-generation sequencing indicates early relapse in stage IA lung adenocarcinoma patients. <i>Oncotarget</i> , 2017, 8, 40643-40653.	0.8	4
185	Erlotinib-based doublet targeted therapy versus erlotinib alone in previously treated advanced non-small-cell lung cancer: a meta-analysis from 24 randomized controlled trials. <i>Oncotarget</i> , 2017, 8, 73258-73270.	0.8	4
186	Overexpression of Raf-1 kinase inhibitor protein inhibits cell invasion and migration in lung cancer cells through suppressing epithelial-mesenchymal transition. <i>Translational Cancer Research</i> , 2019, 8, 2295-2306.	0.4	4
187	CHRNA3 rs1051730 polymorphism and lung cancer susceptibility in Asian population: a meta-analysis. <i>Translational Lung Cancer Research</i> , 2015, 4, 104-8.	1.3	4
188	Intrapleural Injection of Anti-PD1 Antibody: A Novel Management of Malignant Pleural Effusion. <i>Frontiers in Immunology</i> , 2021, 12, 760683.	2.2	4
189	Assessing the clinical outcome of nab-paclitaxel in Chinese patients with advanced non-small cell lung cancer. <i>Clinical Respiratory Journal</i> , 2017, 11, 632-639.	0.6	3
190	A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel. <i>ESMO Open</i> , 2017, 2, e000174.	2.0	3
191	Intracavitary chemotherapy with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is not superior to TKI monotherapy in controlling malignant pleural effusion recurrence in EGFR-mutated lung cancer patients. <i>Journal of Thoracic Disease</i> , 2019, 11, 3712-3720.	0.6	3
192	Case Report: A Rare Case of Metachronous Multiple Primary Lung Cancers in a Patient With Successful Management by Switching From Anti-PD-1 Therapy to Anti-PD-L1 Therapy. <i>Frontiers in Immunology</i> , 2021, 12, 683202.	2.2	3
193	Lung adenocarcinoma patient with EGFR 19 exon insert mutation and its response to icotinib. <i>Lung Cancer</i> , 2018, 121, 101-104.	0.9	2
194	The correlation between crizotinib efficacy and molecular heterogeneity by next-generation sequencing in non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, 2948-2959.	0.6	2
195	Development of RECLS score to predict survival in lung cancer patients with malignant pleural effusion. <i>Translational Lung Cancer Research</i> , 2021, 10, 1318-1326.	1.3	2
196	The expression landscape of JAK1 and its potential as a biomarker for prognosis and immune infiltrates in NSCLC. <i>BMC Bioinformatics</i> , 2021, 22, 471.	1.2	2
197	Preface on "pulmonary nodules special issue for lung cancer". <i>Translational Lung Cancer Research</i> , 2017, 6, 1-2.	1.3	2
198	Multicenter study of diagnostic procedures, genetic aberration analysis, and first-line treatment of lung cancer in Jiangsu Province, China. <i>Thoracic Cancer</i> , 2018, 9, 376-383.	0.8	1

#	ARTICLE	IF	CITATIONS
199	Diagnosis status and pathological diagnosis derived treatment of elderly lung cancer patients over 75 years old. <i>Translational Cancer Research</i> , 2019, 8, 87-95.	0.4	1
200	Could cell division cycle protein 42 be a target for lung cancer treatment?. <i>Translational Cancer Research</i> , 2019, 8, 312-318.	0.4	1
201	comparison to DP in the first-line treatment of phase IIIb/IV squamous-cell NSCLC (JSLCG-001): A multicenter, open-label, randomized phase III controlled study (NCT: 02513342).. <i>Journal of Clinical Oncology</i> , 2019, 37, e20541-e20541.	0.8	1
202	Carcinoembryonic antigen in pleural effusion of patients with lung adenocarcinoma: a predictive marker for EGFR mutation. <i>Translational Cancer Research</i> , 2019, 8, 1027-1034.	0.4	1
203	Simultaneous in situ detection of protein expression of multiple tumor markers of circulating tumor cells and heteroploid of chromosome 8 in primary lung cancer. <i>Annals of Translational Medicine</i> , 2021, 9, 1772-1772.	0.7	1
204	How to diagnose pulmonary nodules: from screening to therapy. <i>Translational Lung Cancer Research</i> , 2017, 6, 3-5.	1.3	0
205	The pulmonary nodule "rediscovered" by pneumonia: a case report. <i>Translational Lung Cancer Research</i> , 2017, 6, 92-96.	1.3	0
206	Neutrophil to lymphocyte ratio as a prognostic indicator for advanced non-small cell lung cancer patients: A retrospective study.. <i>Journal of Clinical Oncology</i> , 2012, 30, e18082-e18082.	0.8	0
207	Gefitinib as third-line re-challenge treatment in advanced NSCLC patients with <i>EGFR</i> activating mutation who benefited from first-line gefitinib treatment followed by second-line chemotherapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9035-9035.	0.8	0
208	Multiple intercostal neurilemmomas in a Chinese woman. <i>Journal of Cancer Research and Therapeutics</i> , 2018, 14, 1220.	0.3	0
209	A pilot trial assessing apatinib combined with docetaxel (DTX) as second-line chemotherapy for EGFR negative advanced non-small-cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2018, 36, e21113-e21113.	0.8	0
210	Efficacy and safety of IBI305 compared with bevacizumab in advanced non-squamous NSCLC patients as first-line treatment in a randomized, double-blind, phase III study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9095-9095.	0.8	0
211	Status quo and prospects of the translational research on lung cancer in China. <i>Translational Lung Cancer Research</i> , 2012, 1, 91-3.	1.3	0
212	Induction of type II alveolar epithelial cells apoptosis in mouse by lipopolysaccharide does not require TNF-alpha. <i>Chinese Medical Journal</i> , 2003, 116, 625-9.	0.9	0